A phase 3, randomized, double-blind, parallel-group, multinational trial of intravenous telavancin versus vancomycin for treatment of hospital-acquired pneumonia with a focus on patients with infections due to methicillin-resistant Staphylococcus aureus

Trial Profile

A phase 3, randomized, double-blind, parallel-group, multinational trial of intravenous telavancin versus vancomycin for treatment of hospital-acquired pneumonia with a focus on patients with infections due to methicillin-resistant Staphylococcus aureus

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Telavancin (Primary) ; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTAIN 1
  • Sponsors Theravance
  • Most Recent Events

    • 01 Dec 2016 Results of ATTAIN 1 and ATTAIN 2 studies assessing the telavancin minimum inhibitory concentration values using revised broth microdilution method (rBMD) were published in the Infectious Diseases and Therapy.
    • 01 Nov 2016 Results published in the Media Release
    • 01 Nov 2016 Results of a retrospective analyses from ATTAIN studies presented at IDWeek 2016, as reported by a Theravance Biopharma media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top